克拉屈滨联合或延迟利妥昔单抗一线治疗毛细胞白血病随机II期研究
主要终点6个月时无MRD完全缓解率CDAR组97% vs 延迟组24%(P<.0001),中位随访96个月时94% vs 12%维持无MRD。
要点
- 同步利妥昔单抗显著提高无MRD完全缓解率(97% vs 24%)。
- 同步组96个月时94%维持无MRD,延迟组仅12%。
- 同步组3/4级血小板减少更常见但无出血。
核心结论
- 一线克拉屈滨同步利妥昔单抗较延迟利妥昔单抗大幅提高无MRD完全缓解率,并显著延长无MRD生存。
主要发现
- 6个月时CDAR组 vs 克拉屈滨单药:CR率100% vs 88%(P=.11),无MRD完全缓解率97% vs 24%(P<.0001,主要终点),血无MRD率100% vs 50%(P<.0001)。
- 中位随访96个月,CDAR组94% vs 延迟组12%维持无MRD。
- 延迟利妥昔单抗组21例可评估患者中67%达到无MRD完全缓解(P=.0034),持久性低于CDAR组(P=.0081,风险比0.094 favoring CDAR)。
- 延迟组12例在末次利妥昔单抗后6-104个月(中位78个月)再评估时仍无MRD。
- CDAR组 vs 克拉屈滨单药:3/4级血小板减少59% vs 9%(P<.0001),血小板输注35% vs 0%(P=.0002),但4周时中性粒细胞(P=.017)和血小板(P=.0015)计数更高。
临床怎么用
- 初治毛细胞白血病可考虑克拉屈滨同步利妥昔单抗以提高无MRD缓解率。
- 同步方案需注意血小板减少和输注风险,但4周血细胞恢复更优。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Single-agent purine analog, usually cladribine, has been the standard first-line therapy of hairy cell leukemia (HCL) for 30 years. High complete remission (CR) rates often include minimal residual disease (MRD), leading to relapse and repeated treatments. Rituximab can clear MRD, but long-term results are unknown and optimal timing of rituximab undefined. PATIENTS AND METHODS: Patients were randomly assigned to first-line cladribine 0.15 mg/kg intravenously days 1-5 with 8 weekly doses of rituximab 375 mg/m2 begun either day 1 (concurrent, CDAR) or ≥ 6 months later (delayed) after detection of MRD in blood. MRD tests included blood and bone marrow (BM) flow cytometry, and BM immunohistochemistry. RESULTS: Sixty-eight patients with purine analog-naïve classic HCL were randomly assigned 1:1 to concurrent versus delayed arms. At 6 months after CDAR versus cladribine monotherapy, CR rates were 100% versus 88% (P = .11), MRD-free CR rates 97% versus 24% (P < .0001, primary end point), and blood MRD-free rates 100% versus 50% (P < .0001), respectively. At 96 months median follow-up, 94% versus 12% remained MRD free. Compared with CDAR, delayed rituximab after cladribine achieved lower rate (67% of 21 evaluable patients; P = .0034) and durability (P = .0081, hazard radio favoring CDAR, 0.094) of MRD-free CR. Nevertheless, 12 patients in the delayed arm remained MRD free when restaged 6-104 (median, 78) months after last delayed rituximab treatment. Compared with cladribine monotherapy, CDAR led to brief grade 3/4 thrombocytopenia (59% v 9%; P < .0001) and platelet transfusions without bleeding (35% v 0%; P = .0002), but higher neutrophil (P = .017) and platelet (P = .0015) counts at 4 weeks. CONCLUSION: Achieving MRD-free CR of HCL after first-line cladribine is greatly enhanced by concurrent rituximab and less so by delayed rituximab. Longer follow-up will determine if MRD-free survival leads to less need for additional therapy or cure of HCL.
引用
- Chihara D, Arons E, Stetler-Stevenson M, et al. Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia. J Clin Oncol. 2020. PMID: 32109194. doi:10.1200/JCO.19.02250
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。